Weekend Read: The Brain Economy
Gary Hunt • 17 January 2026
Weekend Read: The Brain Economy
A Culture of Triumphant Living is increasingly being recognised as the New Currency of Power.
We are the world’s most Valuable Modern Selfcare, Consumer Goods, and Consumer Healthcare Asset, Consumption Superpower and Mega force for Progress
The Engine Room of Global Modern Selfcare Economies and the Consumer Landscape
Redefining the Boundaries of Ambition
INVESTING IN PEOPLE, TRUST
AND DERISKING, AND HEALTHY
We Discover. We Make.
We take the Lead
Modern Selfcare Landscape:
(Men's Health, Consumer Health and Development, Healthspan, Lifestyle, Longevity, Nutraceuticals, Nutricosmetics, Brain Health, Organic, Nutrition, Agriculture, Complementary and Integrative Health, Value-Based-and-Integrated Care, Food is Medicine, Medically Tailored Meal Programmes, Life Science OTC, Wellness, Wellness Infrastructure and Human Services upstream and
downstream interventions just to name a few)
Our Modern Self-care, Consumer Goods, and Consumer Health Assets, Value Proposition, Framework, and key focus areas—driven by my 20+ years of Healthy Structural Performance, Operational Resilience, and Efficacy—are powerful, transformative, it's policy rich and truly seminal and deeply rooted in Human Agency, & Economics that supports a
Culture of Triumphant Living.
They represent a major force in shaping and defining the global Consumer and Economic landscapes
The Global Structure Diamond International and Advocacy, and The Global Structure Network Limited are trusted to lead—
by Consumers, CEOs, Stakeholders and Industry.
Investors, Stakeholders and Brands can directly contact us here:
info@theglobalstructurenetwork.com
gary@gsdiandadvocacy.co.uk
gary@theglobalstructurenetwork.com
Opportunity, Affordability, and
Equality of Opportunity
For the latest Sector News, visit here: https://www.gsdiandadvocacy.co.uk/news
STICK WITH US
The Global Structure Network Limited and The Global Structure Diamond International & Advocacy remain your go-to platforms for all things 'You'
in Modern Selfcare, Consumer Goods, and Consumer Health, with a focus on fostering a Culture of Triumphant Living.
Our work is underpinned by the Consumer Balance Sheet and Consumer Net Worth, with a focus on increasing that Net Worth in towns and cities around the world.
Wealth Creation is back on the Global Agenda
Global Poverty Inc. should not mistake our resolve, nor the resolve of our investors, the CEOs and stakeholders investing in our expansion, or the Consumers determined to raise their ambitions and expectations.
The Global Structure Network Limited — a pioneering, global consumer-to-thrive market maker — together with its complementary engine, The Global Structure Diamond International & Advocacy, the world’s first Global Consumer Brain Trust
Who We Are
The Global Structure Network Limited www.theglobalstructurenetwork.com
and The Global Structure Diamond International & Advocacy represent a transformative global Consumer Framework and ecosystem — purpose-built to unlock the full potential of the Modern Selfcare economy.
We are:
A Consumer Brain Trust: A resource for individuals worldwide who aspire to a Culture of Triumphant Living — where development, health, and capability enhancement drive personal and collective advancement.
A Global Marketplace: Facilitating commerce, innovation, and investment in Modern Selfcare products, services, and capital — connecting consumers, creators, and investors across borders.
A Platform for Exchange: Where consumers see an extension of their priorities and ambitions, and businesses discover opportunity across markets, sectors, and cultures.
Our Values:
We do not build programmes; we architect systems. Our values are not aspirational slogans — they are the operational logic of a civic infrastructure designed to reconstitute how societies conceptualise health, capability, and consequence. We architect civic infrastructure not to manage crisis, but to proliferate capability, consequence, and belonging.
Structural Belonging
We design for authorship, not access. Belonging, in our framework, is infrastructural — embedded in the systems that enable individuals and communities to shape, not simply navigate, the civic and economic landscapes around them.
Regenerative Value as Doctrine
We treat populations as regenerative portfolios — capable of compounding civic, fiscal, and ecological value. Our work reframes health, education, and capability as productive assets, not liabilities to be managed.
Interdisciplinary Intelligence
We operate across domains — linking economics, psychology, design, and governance into coherent systems. This synthesis allows us to build infrastructures that are technically sound, culturally resonant, and institutionally scalable.
Consequence-Driven Design
We design with intentionality. Every intervention is legible to long-horizon impact, civic resilience, and structural coherence. We resist the aesthetics of innovation for its own sake; we pursue design as consequence.
Quiet Authority
We do not trade in spectacle. Our voice is layered, reflective, and structurally grounded — inviting engagement through rigour, not noise. We carry critique, but it is embedded in systems that speak for themselves.
Civic Ambition
We elevate wellbeing beyond clinical metrics. Triumphant Living, in our lexicon, is a civic ambition — realised through embedded capability, operational resilience, and structural authorship across goods, services, and governance.
Institutional Scalability
We build systems that are legible to capital, policy, and governance. Our infrastructures are designed to be adopted by ministries, development banks, and ESG investors — without dilution of vision or complexity.
Prevention as Strategy and Doctrine
We embed prevention into fiscal architecture and public policy — not as an adjunct, but as economic logic. We treat upstream interventions as strategic levers for long-term productivity and civic enablement.
Our Vision Is Structured Around Four Core Pillars:
- Redefining the Boundaries of Ambition
- Performance, Productivity and Prosperity
- Human Capital Formation
- A Cultural Platform
Together, we form what we call the Consumer Internet — a dynamic infrastructure for productivity, prosperity, and empowerment.
This is the underlying infrastructure of a redefined global consumer landscape. It enables:
- The flow of products, services, and capital in a new capability economy
- The scale-up of preventive, developmental, and capability-enhancing solutions
- The integration of consumer empowerment, affordability, and agency into system-level design
- A resilient platform, aligned with private growth for the public good.
At our core, we are a global Modern Selfcare marketplace — delivering branded products, services, and consumer capital in service to Wealth Creation Assets, Health, and Development. Our model spans everything from over-the-counter consumer health and Modern Selfcare items to food, clothing, cosmetics, and beverages — touching every sector that defines the Modern Selfcare economy. https://www.gsdiandadvocacy.co.uk/the-global-structure-network-limited-and-the-global-structure-diamond-international-and-advocacy-stand-as-islands-of-conscious-consumer-power-amidst-a-sea-of-transactions-across-the-global-consumer-la
Modern Selfcare Landscape
- Men’s Health
- Healthspan
- Longevity
- Lifestyle
- Drinks
- Consumer Health and Development
- Skin immunology and Skin Care
- Selfcare, Consumer Goods, and Consumer Health Print and other Media
- Nutraceuticals
- Nutricosmetics
- Organic
- Nutrition
- Agriculture
- Complementary and Integrative Health
- Value-Based-and-Integrated Care
- Food is Medicine
- Consumer Goods with new, unique, and distinct Value Propositions.
- Medically Tailored Meal Programmes
- Life Science OTC
- Wellness and Wellness Infrastructure
- The Brain Economy
- Human Services upstream and downstream interventions, just to name a few
For investors, this represents a structurally advantaged opportunity to participate in the rise of a new economic paradigm — one that is consumer-led, policy-aligned, and globally scalable. We are not simply launching products; we are activating an ecosystem designed to deliver long-term value, cultural relevance, and commercial resilience.
Who we Are, How we Partner, and What we Value is — for us — a Competitive Edge, a critical Value Driver, a Strategic Distinction, and a Market-Defining Strength.
We are committed to building significant and enduring initiatives with CEOs, investors, and companies that share our ambition, align with our agendas, and uphold our values.
Building a company of this scale is demanding, yet we have done the difficult work of transforming our vision into a tangible and investable reality.
Today, strategic partnership is central to our agenda. By aligning with investors, industry leaders, and policy stakeholders who share our ambition, we do not simply accelerate growth — we co‑create it. These partnerships are reciprocal, reinforcing one another and ensuring that value flows in both directions: strengthening our expansion while enhancing and amplifying social, structural, and economic value for those who join us.
This approach embeds intimacy and consequence into collaboration. Every partnership enhances the long‑term value of our Modern Self‑care mission — creating scalable opportunities, driving sustainable performance, and positioning all participants as co‑authors of a redefined global consumer economy.
Remember, we don’t give our voice to anyone. Let’s connect. Contact us:
info@theglobalstructurenetwork.com | gary@gsdiandadvocacy.co.uk | gary@theglobalstructurenetwork.com
The Scale and Weight of the J.P. Morgan Healthcare Conference
The J.P. Morgan Healthcare Conference (JPM) is widely regarded as the largest and most influential healthcare investment symposium in the world.
Its scale is unmatched:
8,000–9,500 attendees in 2026, including executives, investors, policymakers, analysts, and media
This concentration of global decision‑makers
makes JPM the closest thing the healthcare sector has to an annual economic summit
— where capital, science, policy, and strategy converge.
Who Converges at JPM — and Why It Matters
JPM draws the full architecture of the global health economy into one place:
Pharmaceutical and Biotech CEOs:
They use JPM to announce pipelines, strategic pivots, and M&A intent.
Examples from 2026 include:
- Johnson & Johnson
- Eli Lilly
- GSK
- Novartis (explicitly signalling ambitions to “win in the neuroscience space”
- Including:
- Venture capital
- Private equity
- Hedge funds
- Sovereign wealth funds
- Institutional asset managers
They attend because JPM sets the investment tone for the entire year.
Policymakers and Global Health Leaders:
Their presence signals that healthcare is now a geopolitical and economic priority, not just a clinical one.
Innovators, Startups, and Scientific Leaders:
From AI‑drug discovery to neurotech, metabolic therapeutics, and immunology.
Media and Analysts:
STAT, Evaluate, BioSpace, and others shape the narrative that markets respond to.
This is the only moment each year when the entire global healthcare ecosystem is physically in one place.
The Deal‑Making Power of JPM (2026 Examples)
JPM is where the largest deals of the year are often announced or negotiated.
In 2026, public reporting confirmed:
Mega‑Deals Announced at JPM 2026:
- Johnson & Johnson → $14.6 billion acquisition of Intra‑Cellular Therapies
- Eli Lilly → $2.5 billion acquisition of Scorpion Therapeutics
- GSK → up to $1.15 billion acquisition of IDRx
- Additional Neuroscience and Oncology Deals
- AbbVie → nearly $5 billion for rights to RemeGen’s PD‑1/VEGF bispecific therapy
- Novartis → $1.5 billion deal with SciNeuro Pharmaceuticals for Alzheimer’s‑related assets
Projected Deal Flow
Analysts expected $10+ billion in additional transactions during the week as companies sought to diversify portfolios and strengthen market positions.
In total, JPM 2026 saw well over $20 billion in publicly reported deal activity — and significantly more in private negotiations.
Why JPM Matters for the Global Healthcare Landscape
It Sets the Strategic Agenda for the Year
Evaluate’s pre‑event report notes that JPM “shapes strategies, sparks partnerships, and drives investment decisions across the life sciences sector”.
It Signals Where Capital Will Flow
In 2026, the spotlight areas were:
- Oncology
- Neuropsychiatry / Neurology
- Haematology
- AI‑enabled drug discovery
These themes now shape global R&D, investment, and M&A priorities.
It Reveals the Future of Healthcare
The clustering of neuroscience, metabolic therapeutics, immunology, and AI at JPM 2026 shows a shift toward:
- capability‑oriented healthcare
- precision medicine
- digital biomarkers
- neuro‑centric innovation
It Influences Policy and National Health Strategy
Because policymakers attend, JPM shapes:
- reimbursement frameworks
- regulatory expectations
- national innovation agendas
It Accelerates Global Competition
When companies like Novartis publicly declare ambitions to “win in neuroscience,” it forces competitors to respond — reshaping pipelines and capital allocation across the sector.
The J.P. Morgan Healthcare Conference is the annual centre of gravity for global healthcare
— where 9,500 leaders converge, more than $20 billion in deals are struck, and the scientific, financial, and strategic direction of the entire sector is set for the year ahead.
The Brain Economy
Executive Summary
The 2026 J.P. Morgan Healthcare Conference (JPM 2026) provided clear evidence that neuroscience has moved to the centre of global healthcare strategy. Public reporting confirms that neuropsychiatry and neurology were among the conference’s leading therapeutic spotlight areas, and that major pharmaceutical companies used the forum to signal expanded investment and strategic intent
in neurosciencePharmaceutical Technology. This aligns directly with the emerging Brain Economy — an economic belief system recognising that brain health is a determinant of productivity, participation, and long term economic growth. Current estimates place the economic burden of brain related conditions at $5 trillion annually, a figure cited by both the World Economic Forum and the McKinsey Health Institute. The following analysis synthesises verifiable JPM 2026 signals with the broader structural forces shaping the Brain Economy.
Scaling What Works, Shaping What’s Next
A structural brief on system redesign and capability‑driven growth.
Our Major Areas of Foci
For years, our organisation has championed the Brain Economy through five interconnected domains that together form the capability architecture of modern life:
- Neurological Wellbeing
- Metabolic Wellbeing
- Immune System Wellbeing
- Healthy Ageing
- Human Services
These domains were not chosen for their thematic appeal; they were chosen because they represent the structural determinants of human capability. JPM 2026 has now begun to reflect — and in some cases, adopt — the very logic we have been advancing: that the future of economic performance will be shaped by the systems that protect, enhance, and extend the brain’s capacity to function, adapt, and thrive. The Brain Economy: A Structural Interpretation Anchored in JPM 2026
Positioned for Growth: From the Global Synchronisation
A macroeconomic analysis of global synchronisation and structural headwinds.
The 2026 J.P. Morgan Healthcare Conference did not announce the Brain Economy; it revealed it. The conference’s agenda, its strategic disclosures, and its ecosystem clustering all pointed to a world beginning to reorganise around cognitive, emotional, and behavioural capability.
Nelson Advisors’ preview of JPM 2026 stated that “conference agendas and guides flag late stage oncology, neuropsychiatry/neurology and hematology as the key therapeutic hotspots”. A second Nelson Advisors analysis reinforced this, noting that “JPM 2026 agendas and attendee guides emphasise oncology, neuropsychiatry/neurology, and hematology as the leading therapeutic spotlight areas”nelsonadvisors.co.uk. This is a quiet but decisive shift: neuropsychiatry and neurology are no longer peripheral scientific pursuits but central pillars of global healthcare investment.
Pharmaceutical Technology reported that Novartis used its JPM 2026 presentation to outline ambitions to “win in the neuroscience space”
through mergers and acquisitions and licensing deals. When a global pharmaceutical leader frames neuroscience as a competitive frontier, it signals a reordering of priorities across the entire sector.
The Neuroscience Innovation Forum, held at the start of JPM week, described its gathering as bringing together “leaders in neuroscience… at the start of JP Morgan Healthcare Week”. This clustering of scientific, financial, and technological actors around brain health is not incidental; it is structural convergence.
These signals collectively affirm what we have long argued: the brain is becoming the most valuable economic asset of the 21st century.
The Economic Burden: A Clarifying Frame
The World Economic Forum estimates that “brain disorders are estimated to cost the global economy $5 trillion every year.” A separate WEF analysis, drawing on McKinsey Health Institute data, reiterates that “brain health disorders cost the global economy $5 trillion annually.” These figures represent lost productivity, diminished workforce participation, increased healthcare expenditure, and the long term erosion of human potential.
This burden reframes brain health as economic infrastructure. It becomes a variable that finance ministries, central banks, and institutional investors can no longer treat as external to economic planning. It becomes a determinant of national competitiveness, fiscal stability, and social cohesion.
Affordability as Economic Infrastructure
A structural doctrine on affordability as the foundation of capability, participation, and economic resilience.
This is the intellectual foundation of the Brain Economy — and it is the foundation we have been building upon for years.
JPM 2026 did not merely highlight neuroscience; it illuminated the broader capability systems that underpin the Brain Economy — the very systems we have placed at the centre of our agenda. Public reporting confirms that the conference’s thematic emphasis aligns directly with our five major areas of foci, demonstrating that the global healthcare and investment community is now moving toward the conceptual ground we have championed for years.
Neurological Wellbeing
The conference’s emphasis on neuropsychiatry, neurodegeneration, and neuro immunology directly validates our long standing focus on the brain as the primary engine of human capability. Nelson Advisors reported that “conference agendas and guides flag late stage oncology, neuropsychiatry/neurology and hematology as the key therapeutic hotspots”. Pharmaceutical Technology reinforced this by noting that Novartis used its JPM presentation to outline ambitions to “win in the neuroscience space”Pharmaceutical Technology. The Neuroscience Innovation Forum further underscored the sector’s prominence by convening leaders across pharma, biotech, neurotech, diagnostics, and investment communities at the start of JPM week.
Metabolic Wellbeing
The metabolic revolution — including GLP 1 expansion and the emerging metabolic cognitive linkages — reinforces our position that metabolic stability
is foundational to cognitive clarity, emotional regulation, and behavioural resilience. C&EN’s coverage of JPM 2026 highlighted that “GLP 1 pills, and immunology” were among the defining themes of the conference. News Minimalist summarised that “the GLP 1 weight loss drug market is booming with new pill approvals and intense competition” and that “immunology research shows promise across various diseases”nelsonadvisors.co.uk.
These developments validate our long standing argument that metabolic wellbeing is not a lifestyle variable but a capability determinant
— one that shapes energy, cognition, emotional stability, and long term resilience.
Immune System Wellbeing
Precision immunology — and specifically neuro immunology — was a visible theme across JPM 2026. C&EN reported that immunology was a major area of focus for biopharma leaders at the conference. News Minimalist similarly noted that “immunology research shows promise across various diseases” and was a central theme of JPM 2026 nelsonadvisors.co.uk.
This emphasis confirms the deep interdependence between immune signalling, mood, cognition, and long term brain health — a relationship we have championed as central to capability.
2026–2030: A Transformative Outlook
The period from 2026 to 2030 will be defined by the institutionalisation of the Brain Economy. Neuroscience will continue to attract capital, talent, and political attention. The economic burden of brain related conditions will force governments to integrate brain health into national productivity strategies. Consumers will increasingly demand products and services that enhance cognitive and emotional capability. Investors will seek assets that expand participation and reduce system pressure. And Modern Self Care will become the operating system through which these shifts are enacted.
The argument is not that neuroscience will grow; it is that economies cannot grow without it. JPM 2026 did not declare this explicitly, but its agenda, its signals, and its strategic disclosures made the direction unmistakable. The Brain Economy is emerging not because institutions are choosing it, but because the world is demanding it.
The Flexible Transaction Playbook
The structural operating system for capability → mobility → productivity → resilience.
JPM 2026 highlighted multiple areas of rapid advancement, including:
- next‑generation antidepressants and anxiolytics
- cognitive‑enhancement therapeutics
- precision neuroimmunology
- digital biomarkers for mood, cognition, and behaviour
- AI‑enabled target discovery in neurodegeneration
Across analyst notes, biotech commentary, and day‑by‑day summaries, several themes were consistently emphasised:
Neuropsychiatry as a major dealmaking hotspot
Neuropsychiatry and neurology were repeatedly cited as one of the three dominant therapeutic areas (alongside oncology and haematology).
- Biomarker‑linked CNS assets
- Analysts highlighted:
- companion diagnostics
- biomarker‑enabled neuropsychiatry
- digital and physiological biomarkers for CNS trials
Precision neuroimmunology
Including:
- BTK inhibitors
- microglial targets
- neuroinflammation pipelines
Cognitive‑enhancement therapeutics
Including:
- neurodegeneration
- cognitive impairment
- neuroplasticity therapeutics
For investors, the message emerging from JPM 2026 is unambiguous: the centre of gravity in global healthcare is shifting toward the systems that protect, enhance, and extend human capability. Neuroscience, metabolic health, immunology, and healthy ageing are no longer discrete therapeutic categories; they are the foundational pillars of the Brain Economy — an economy in which cognitive, emotional, and behavioural capacity determine productivity, participation, and long‑term economic resilience.
The $5 trillion annual burden of brain‑related conditions is not simply a healthcare challenge; it is a structural drag on growth, competitiveness, and fiscal stability. As governments begin to integrate brain health into national productivity strategies, and as employers confront the economic cost of cognitive and emotional strain, capital will increasingly flow toward assets that expand human capability and reduce system pressure.
JPM 2026 made this trajectory visible. The prominence of neuropsychiatry and neurology, the acceleration of GLP‑1 and metabolic therapeutics, the rise of precision immunology, and the clustering of neuroscience‑focused events at the start of JPM week all point to a market reorganising around capability
rather than condition. The companies that framed neuroscience as a competitive frontier were not signalling a thematic interest; they were signalling a structural bet on the future of economic performance.
For investors, the opportunity is clear. The next decade will reward those who recognise that brain health is not an adjacent category but the organising logic of modern healthcare. The winners will be the firms that build, acquire, or back the platforms, therapeutics, diagnostics, and services that strengthen the capability architecture of society. The Brain Economy is not a trend; it is an economic realignment. JPM 2026 did not declare it — it confirmed it.
The investment thesis is straightforward: as the world shifts from treating illness to expanding capability, value will accrue to the companies that enable people to think, feel, and function at their highest potential.
Gary — Founder & Architect
The Global Structure Network Limited and The Global Structure Diamond International & Advocacy Architecting the Modern Self‑Care Economy & the Consumer‑to‑Thrive System
Associated Sites:
LinkedIn:
Global Competition Between Capital Environments: Environmental Physics, Liquidity Architecture, and Jurisdictional Advantage.
An Application of Capital Environment Theory
The Banner of Capital and the Capital Environment Foundations of Capital Environment Theory (CET)
Property, Power, and Jurisdictional Migration: ExxonMobil, the Texas Business Court, and the Structural Evolution of Corporate Governance
NatWest Group and the Re‑Emergence of the Strategic Bank
From the Experience Economy to the Capability Economy
Shareholder Activism Readiness Newsletter
NAO - Governance, Risk, and State Capability in a Decisive Decade
The 2010 Controlled Land Order: A Structural‑Economic Assessment of the Classification of Aldi and Lidl
A Macro-Structural Thesis for Capability Infrastructure and Long-Duration Institutional Capital
